Department of Radiology, Centro Universitario de Imagen Diagnóstica, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Av Gonzalitos y Madero, San Nicolás de los Garza, Monterrey 66451, Nuevo León, Mexico
Auto-generated profile, based on publicly available information
Guillermo Elizondo-Riojas
Department of Radiology, Centro Universitario de Imagen Diagnóstica, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Av Gonzalitos y Madero, San Nicolás de los Garza, Monterrey 66451, Nuevo León, Mexico
BACKGROUND AND PURPOSE: Effective management of patients with brain tumors depends on accurate detection and characterization of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors. MATERIALS AND METHODS: This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose = 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2–14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from “poor” to “excellent.” Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site. RESULTS: For all 3 readers, images of most patients (>90%) were scored good or excellent for overall lesion visualization and characterization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion percentage enhancement being higher with gadobutrol (P < .001). Diagnostic confidence was high/excellent for all readers in >81% of the patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observed with gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain. CONCLUSIONS: The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors was demonstrated.
The 25-year history of the RSNA Committee on International Radiology Education and its varied global radiology programs is explored, as well as the committee’s newest initiative, the Global Learnin... The Radiological Society of North America (RSNA) Committee on International Radiology Education (CIRE) has worked for the past 25 years to create academic programs oriented to the needs of internat...
1 November 2020 in Journal of Vascular and Interventional Radiology
“Just Accepted” papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review ...
1 November 2021 in Journal of the American College of Surgeons
The Trendelenburg position was originally described (1860) with the patient in supine decubitus with a head-down tilt of 45o below the breech plane to favor venous return by gravity, for central venous catheterization. This position is not viable or clinically practical. The objective was to determine the most comfortable angulation and the morphological changes of the right internal jugular vein (RIJV).